74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
STRATEC Biomedical AG
Closed
23.6 -1.05
Overview
Share price change
24h
Min
22.9
Max
23.75
Income | -2.9M 549K |
|---|---|
Sales | -11M 57M |
P/E Sector Avg | 29.695 28.692 |
Dividend yield | 2.16 |
Profit margin | 0.959 |
Employees | 1,462 |
EBITDA | -3.3M 7.1M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +61.94% upside |
Dividend yield Sector Avg | 2.16% 3.67% |
|---|---|
Next Earnings | 29 Apr 2025 |
Market Cap | 296M |
|---|---|
Previous open | 24.65 |
Previous close | 23.6 |
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
STRATEC Biomedical AG Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
STRATEC Biomedical AG Forecast
Price Target
By TipRanks
61.94% upside
12 Months Forecast
Average 40 EUR 61.94%
High 41 EUR
Low 39 EUR
Based on 3 Wall Street analysts offering 12 month price targets forSTRATEC Biomedical AG - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About STRATEC Biomedical AG
Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers; and offers complex consumables for diagnostics and medical applications. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
